Company Profiles
Portfolio 21 Holdings
- ABB
- Abengoa
- Acciona
- Accor
- Adobe
- Air Liquide
- American Superconductor
- Apogee
- Applied Materials
- AstraZeneca
- Atlas Copco
- Autodesk
- Aviva
- Baxter
- British Land
- British Sky Broadcasting
- Canadian Pacific Railway
- Canon
- Carrefour
- Cisco Systems
- Cosan
- Dell
- Denso
- Deutsche Post
- East Japan Railway
- Eaton
- Echelon
- Ecolab
- EDF Energies Nouvelles
- EDP Renovaveis
- Electrolux
- H. Lundbeck
- Henkel
- Hennes & Mauritz (H&M)
- Herman Miller
- Hewlett-Packard
- HSBC
- Hyflux
- Iberdrola Renovables
- IBM
- Intel
- Itron
- Johnson & Johnson
- Johnson Controls
- Johnson Matthey
- Kao
- Kingfisher
- Kurita
- Marks & Spencer
- Mitsubishi Electric
- Mitsui O.S.K. Lines
- MTR
- Munich Re
- National Grid
- Natura Cosmeticos
- Netapp
- Nike
- Nokia
- Novartis
- Novo Nordisk
- Novozymes
- Nucor
- Olympus
- Ormat
- Philips Electronics
- Portland General Electric
- Potlatch
- Praxair
- Prologis
- Red Electrica
- Reed Elsevier
- Roche
- Royal Bank of Canada
- Schneider Electric
- Schnitzer Steel
- Scottish & Southern Energy
- Severn Trent
- Sharp
- Shimano
- Siemens
- Skanska
- SKF
- Smith & Nephew
- Sonoco
- Staples
- SunPower
- Svenska Cellulosa (SCA)
- Swiss Re
- Tandberg
- Teijin
- Telefonica
- Tennant Company
- Tesco
- TNT
- Umicore
- Unibail-Rodamco
- Unicredit Group
- United Natural Foods
- Verbund
- Vestas Wind Systems
- VMware
- Volvo Group
- Waters
- Westpac Bank
- Whole Foods Market
- Xerox
Novo Nordisk
Denmark
Novo Nordisk is a pharmaceutical development and manufacturing company. The company's management recognizes the "move to sustainable development . . . can be an opportunity to create competitive advantages, if successfully integrated into the corporate strategy." It understands the planet's limited resources, the increasing pressures on those resources, and the need to live "more off the earth's interest, and less off its capital." Novo Nordisk's largest environmental impacts are associated with its energy, water, and raw materials use. The company is working to reduce its carbon dioxide emissions, in line with the Kyoto Protocol, through energy-saving initiatives and renewable energy purchases. Novo Nordisk has entered into an agreement with DONG Energy (Denmark's largest energy company). DONG will assist Novo Nordisk in identifying energy-saving initiatives, and in return, Novo Nordisk will purchase corresponding quantities of energy from offshore wind farms. Novo Nordisk's waste has increased year on year. Portfolio 21 will continue to monitor the company's plans to assess its sources of waste, with the aim of stabilizing waste volumes.
Biotechnology Involvement
Novo Nordisk's core business is pharmaceutical drug development, manufacturing, and marketing. The company supports the Convention on Biological Diversity that states benefits should be shared "fairly and equitably." Genetically modified organisms used in production are contained and "inactivated" prior to disposal or recycling. The company has a comprehensive and transparent biotechnology policy that addresses concerns of knowledge and containment, uses biotechnology only for medical applications, and meets Portfolio 21's biotechnology investment criteria. Visit our Biotechnology Policy for more on this issue.
To the best of our knowledge the above information is accurate and was obtained from sources we believe to be reliable. Neither the information presented above nor any opinion expressed shall be construed as an offer to sell or a solicitation to buy the security. The views expressed are those of portfolio management as of 9/30/09 and may not reflect current opinions or subsequent events.